HOME >> MEDICINE >> NEWS
Where do new therapies work best?

An observational study to investigate how new therapies for rheumatic diseases perform across different conditions has revealed that they may be more successful in certain conditions. The data is presented today at the Annual European Congress of Rheumatology in Amsterdam, the Netherlands. An increasing proportion of patients with rheumatic conditions such as ankylosing spondylitis (AS), psoriatic arthritis (PsA) and rheumatoid arthritis (RA) now receive anti-TNF treatment a newer group of drugs which are used to reduce inflammation and manage disease activity*. Study lead Dr Marte Heiberg, of the Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, told delegates: "Many studies have focused on efficacy of these drugs, however less is known about comparative real life performance of these drugs across different diagnostic groups".

The study was conducted across 5 Norwegian Rheumatology Departments and included 796 RA patients, 162 PsA patients and 211 patients with a diagnosis of AS. All patients were on an anti-TNF treatment regimen of infliximab, etanercept or adalimumab +/- methotrexate (MTX). The primary outcome was the number of patients still on therapy at one year known as the adherence to therapy. RA was used as the reference group and within each diagnostic group the adherence to anti-TNF monotherapy versus TNF+MTX was compared.

The relative risk for withdrawal from TNF+MTX versus anti-TNF monotherapy was 0.54 for RA patients, 0.49 for PsA patients and 0.83 for AS patients, demonstrating that combination treatment strategy of anti-TNF+MTX worked better than anti-TNF monotherapy in patients with RA and PsA. Although the crude one-year overall drug adherence rates for anti-TNF therapy were superior in patients with PsA and AS compared to RA, after adjusting for age, gender and concomitant MTX, the adherence to anti-TNF treatment were similar in patients with RA and PsA whereas the adherence to anti-TNF treatment was superior in patients
'"/>

Contact: Mia Gannedahl
mia_gannedahl@uk.cohnwolfe.com
44-207-331-2325
European League Against Rheumatism
22-Jun-2006


Page: 1 2

Related medicine news :

1. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
2. Where is the most dangerous place to travel over the holiday?
3. Where should I have my outpatient surgery?
4. Where are medical graduates practising and why?
5. Where the brain organizes actions
6. Where we change our mind
7. Where your brain wires itself to like (name your favorite brand)
8. Where lifes memories are stored
9. Future therapies for stroke may block cell death
10. Antifolate therapies found effective against certain type of malaria
11. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Where new therapies work best

(Date:2/28/2015)... (PRWEB) February 28, 2015 Mew and ... announced that they now provide business consulting services in ... as corporate tax planning and succession planning. Company finances ... to experienced professionals. On top of this, complex Canadian ... handle corporate accounting. As a result, Mew and Company ...
(Date:2/28/2015)... 2015 Vancouver personal injury lawyers at Jiwa ... affected by time limits. They stated that in many cases, ... or even nullify it. Many a time, delays in making ... rights under BC law. As a result, experts at Jiwa ... should consult a personal injury lawyer in order to know ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Indosoft ... software suite for Asterisk, are pleased to announce the ... successful 5.7 and 5.8 versions of Q-Suite, this new ... as a number of new features to the leading ... 2015. , Q-Suite 5.9 will add features to enhance ...
(Date:2/28/2015)... A study out of the University of Oxford ... the treatment of a hereditary ocular condition that leads ... Dr. Robert MacLaren, professor of ophthalmology at the University ... on January 16, 2014 , the study treated six ... mostly affects men and leads to the degeneration of ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 For those ... in person, the Mesothelioma Applied Research Foundation ... on Tuesday, March 3, starting at 9:30 AM. , ... no registration. The broadcast can be accessed through any ... http://www.curemeso.org/symposium . , The Symposium is a unique event ...
Breaking Medicine News(10 mins):Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2
(Date:2/27/2015)... 2015 Roughly three-quarters of pharmacists said ... an interchangeable biosimilar for its branded biologic counterpart ... name, according to a survey published in the ... of Managed Care & Specialty Pharmacy (JMCP). ... pharmacists would feel as confident if the products ...
(Date:2/27/2015)... 27, 2015 Pharmaceutical and biotech marketers are ... for the same indication. This can be a complex ... prevent one of their brands from gaining market share ... recent research by benchmarking firm, Best Practices, LLC, 75% ... rather than together as part of a franchise. Marketers ...
(Date:2/27/2015)... 27, 2015 The role of the Medical ... one thing hasn,t changed: face-to-face meetings are seen as ... Key Opinion Leaders. Yet at the same ... type of interaction, field medical teams within the pharmaceutical ... This is just one of the challenges addressed in ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2
Cached News: